An interventional study of Associative Peripheral Stimulation (APS) 1.0 and Peripheral Neuromuscular Stimulation in Stroke, Stroke, Acute and Stroke, Ischemic, sponsored by Ahmed A. Rahim. Recruiting at 3 sites in Mexico. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-08-30.
Sponsored by Ahmed A. Rahim · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Stroke with a site in Mexico — 11 open to participants now, 14 under way, 3 of them phase 3. Stroke · Mexico.
Among the 52 studies in Stroke with a site in Mexico, this one is the 38th largest by planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 34th registered.
8,281 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →11 of the 52 studies in Stroke with a site in Mexico are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Mexico, Argentina, Australia and 35 more countries
Ages 50+
Instituto Nacional de Rehabilitacion · Sites in Mexico
Ages 18+
Hospital General de Mexicali · Sites in Mexico
Ages 18+
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18–80
Coordinación de Investigación en Salud, Mexico · Sites in Mexico
Ages 35–70
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 25 · Phase 4 2
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 5,081 across the 39 interventional studies, 350 across the 13 observational. Of the 35 that completed or were terminated, 17 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 52 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ahmed A. Rahim as lead sponsor.
Ahmed A. Rahim has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
1 of the studies in Stroke with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06811142Instituto Mexicano del Seguro SocialEarly Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 52 studies in Stroke with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Associative Peripheral Stimulation (APS) is a non-invasive therapy intended for stroke rehabilitation involving transcutaneous electrical muscle stimulation paired with voluntary movement. This pilot study investigates whether APS applied during the acute phase of stroke recovery may reduce impairment and improve function in the affected upper extremity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment
Device: Associative Peripheral Stimulation (APS) 1.0
Control
Device: Peripheral Neuromuscular Stimulation
Associative peripheral stimulation paired with rehabilitative exercises.
Random peripheral stimulation paired with rehabilitative exercises.
Maximum Average of Range of Motion (ROM)
Measure of distal extensor function (wrist and fingers). Unit of measurement: degrees (°). Higher scores indicate better outcomes.
Time frame: 5 weeks
Fugl-Meyer Assessment Upper-Extremity (FMA-UE)
Measure of motor recovery in stroke patients with hemiparesis. Scoring range: 0 to 66. Higher scores indicate better outcomes.
Time frame: 5 weeks
Maximum Average of Range of Motion (ROM)
Measure of distal extensor function (wrist and fingers). Unit of measurement: degrees (°). Higher scores indicate better outcomes.
Time frame: 3 months
Fugl-Meyer Assessment Upper-Extremity (FMA-UE)
Measure of motor recovery in stroke patients with hemiparesis. Scoring range: 0 to 66. Higher scores indicate better outcomes.
Time frame: 3 months
Action Research Arm Test (ARAT)
Measure of four functional domains: grasp, grip, pinch, and gross arm movement. Scoring Range: 0 to 57. Higher scores indicate better outcomes.
Time frame: 5 weeks
Action Research Arm Test (ARAT)
Measure of four functional domains: grasp, grip, pinch, and gross arm movement. Scoring Range: 0 to 57. Higher scores indicate better outcomes.
Time frame: 3 months
Plan to share: No — Individual participant data shall not be made available to other researchers.
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2024, 36 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.